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 ABSTRACT 
 
Methyl-CpG binding domain (MBD) proteins are considered as the decoders of the methyl 
signature on DNA. This highly conserved family of DNA-binding proteins translates the 
information represented by methylation patterns into appropriate functional language. MBD 
proteins bind to the DNA around methylated cytosine bases located particularly in the promoter 
regions, preventing binding of transcription factors and RNA polymerase and thereby repress 
transcription. Region-specific DNA hypermethylation is considered as a characteristic hallmark 
of cancer. MBD proteins are held as the main culprits in perpetuating gene silencing mechanism 
by interacting with a number of protein partners such as HDACs, hence they are now considered 
as potential biomarkers for diagnosis and prognosis of malignant transformation. The present 
study will be conducted to analyse the gene expression status of the methyl-CpG-binding (MBD) 
proteins - MeCP2, MBD1, MBD2, MBD3 and MBD4 in breast cancer after treatment with 
HDAC inhibitors TSA and SFN. Study and characterization of the pattern of binding of the 
MBD proteins will provides a powerful set of epigentic markers for outlining the disruption of 
critical pathways in tumorigenesis. This study based on MBD protein distribution and occupancy 
in a gene and tumor type specific context will define a sensitive molecular detection strategy for 
virtually every human cancer type. 
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INTRODUCTION 
 
Differential gene expression and functional state results essentially from epigenetic 
manipulations of the genetic information through temporal and spatial regulation of gene 
activity. The epigenetic mechanisms entail cellular processes that do not alter the genomic 
sequence and they are believed to elicit and sustain relatively persistent biological effects. DNA 
methylation, post-translational covalent histone modifications such as methylation, acetylation, 
phosphorylation, sumoylation etc., incorporation of histone variants, gene silencing mediated by 
non-coding RNAs, nucleosomal rearrangement, higher order chromatin remodeling and 
transcriptional feedback loops are the important protagonists who modulate the DNA and its 
associated histone proteins to effectively manage the gene expression circuitry. These molecular 
restructuring events function as an interface between the genomic content and the external 
environment. They act as a conduit for the efficient regulation of cellular functions by the 
environment-induced cues to establish steady internal physiological states.  Thus, the epigenetic 
mechanisms work in a rigidly controlled manner to establish a stable cell destiny by eliciting 
distinct transcriptional response in different biological settings. 
DNA methylation is one of the principal epigenetic enforcers participating in cell-specific 
repression of transcriptional activity. It is considered as a fundamental phenomenon orchestrating 
functional re-orientation of the genomic data. It basically acts as a gene silencing mechanism to 
turn off specific genes at crucial junctures during development and differentiation. In 
biochemical language, DNA methylation is a post-synthetic process of addition of methyl groups 
to the cytosine residues in the presence of a co-factor S-Adenosyl Methionine (SAM). The 
enzymes responsible for catalyzing this reaction are known as DNA methyltransferases 
(DNMTs). The methyl tags on the cytosines are however recognized and translated into readable 
genetic language by a family of proteins known as the Methyl-CpG-binding domain (MBD) 
proteins. MBD proteins bind to the DNA around methylated cytosine bases located particularly 
in the promoter regions, thereby preventing binding of transcription factors and RNA 
polymerase. They also interact with a number of protein partners and lead to transcriptional 
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repression and/or heterochromatin formation. Thus, MBD proteins are the readers of the methyl 
code propagated by the DNMTs, deciphering the methyl signature in a functional context. 
Over recent years, it has been firmly established that epigenetic mechanisms play a 
crucial role in provoking deregulated gene function during initiation, maintenance and 
progression of cancer. Any malfunctioning in the epigenomic supervisory system eventually 
affects the way in which the genomic information is inferred, resulting in malignant 
transformation. Thus epigenetic and genetic processes join hands to disrupt the normal activity of 
crucial tumor suppressors, cell-cycle regulatory and other such necessary genes to stimulate 
tumorigenesis. Gene-specific regional hypermethylation and subsequent silencing of tumor 
suppressor genes is regarded as a characteristic hallmark of cancer. This hypermethylation 
induced silencing of tumor suppressor genes in cancer cells is mediated by MBD proteins which 
bind to the methylated promoters, preventing their transcriptional activation in time to stop 
cancer. Hence, targeting of MBD proteins for effectively thwarting the neoplastic progress is 
now considered a potential therapeutic alternative. In the context of the significance of the MBD 
proteins in the epigenomic landscape, the present study was designed to investigate the gene 
expression pattern and profiling of the family of MBD proteins - MeCP2, MBD1, MBD2, MBD3 
and MBD4 in breast cancer. A comparative analysis of the expression levels of different MBD 
proteins after treatment with epigenetic drug TSA (Trichostatin) and SFN (Sulphoraphane) will 
be done to create a diagnostic profile in breast cancer. The project aims to provide a 
comprehensive knowledge about the mechanistic action of the HDAC inhibitors on the gene 
expression of MBD proteins so as to design novel strategies for effective therapeutic targeting in 
breast cancer. The project will help to create an MBD protein based epigenetic profile in a gene 
and tumor type specific context for diagnosis, detection and prognosis. Further investigations 
into the pattern of binding of the MBD proteins in a variety of different cancer tissues will offer 
new insights into the role of MBD proteins in malignant transformation and subsequently pave 
way for combating this prevalent and potentially devastating disease. 
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REVIEW OF LITERATURE 
 
Epigenetics [‘Epi’-above/over/beyond; ‘above’-genetics] is the study of heritable changes 
in gene expression caused by mechanisms other than changes in the underlying DNA sequence 
that result in cell specific functional variations in phenotype. These modifications consist of 
DNA methylation, Histone modifications and Non-coding RNA mediated gene silencing (Fig 1). 
The term ‘epigenesis’ which refers to hypothetical aspects of developmental biology and the 
strategy of genes was coined by C. H. Waddington in 1930. Epigenetic modifications are 
heritable, reversible covalent modifications that work in tandem to orchestrate the transcriptional 
activity of the genome in various biological settings. Recent studies show that the association of 
components of transcriptional regulatory machinery with target genes on mitotic chromosomes is 
a novel epigenetic mechanism that poises genes involved in key cellular processes, such as 
growth, proliferation, and lineage binder, for expression in progeny. 
 
 
Shown here are some well-defined epigenetic mechanisms that include histone modifications, DNA 
methylation, and the noncoding RNA-mediated modulation of gene expression. 
(Adapted from Zaidi et.al, Molecular and cellular biology, 2010) 
Figure 1: Mechanisms of inheritable epigenetics. 
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DNA Methylation-The Epigenetic Writer: 
DNA methylation is the first and most extensively researched epigenetic manipulation. 
DNA methylation frequently occurs in repetitive sequences, and helps to suppress the expression 
and mobility of 'transposable elements. DNA methylation patterns are recognized to be 
established and modified in response to environmental factors by a complex interplay of at least 
three independent DNA methyltransferases (DNMT) -- DNMT1, DNMT3A, and DNMT3B. 
DNMT1 is the most copious methyltransferase in somatic cells, localize to replication foci, has a 
10–40-fold leaning for hemimethylated DNA and interacts with the proliferating cell nuclear 
antigen (PCNA). By preferentially modifying hemimethylated DNA, DNMT1 transfers 
methylation patterns to a newly synthesized strand after DNA replication, and hence is often 
referred to as the ‘maintenance' methyltransferase. DNMT3A and DNMT3B, known as the de 
novo methyltransferases add methyl marks to newly synthesized daughter DNA strands and 
faithfully propagate the methyl patterns across successive generations. DNA methylation, in 
general is a repressive mark on the genome playing crucial role during development and 
differentiation by influencing the transcriptional machinery and inducing gene silencing (Kar et 
al., 2012). 
 
 
The addition of methyl groups onto the cytosine residues in the promoter regions of the DNA prevents 
transcription factors from binding to it and thus leads to gene silencing. 
(Adapted from Wade, Bio Essays, 2001) 
Figure 2: DNA Methylation and Gene Silencing. 
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Methyl-Binding Domain Proteins-The Epigenetic Readers: 
The correlation between DNA methylation and transcriptional inactivity is well 
recognized. However, a causative role for CpG methylation in suppression of transcription has 
often been a subject for debate. Although many silenced genes are linked with dense CpG 
methylation, this epigenetic mark could be a downstream consequence of transcriptional 
inactivity rather than an active participant in the process of repression. However, the 
identification of a family of proteins that bind to DNA containing methylated CpG dinucleotides 
established a causative link between CpG methylation and repression of transcription. This 
family of proteins, known as Methyl-Binding Domain (MBD) proteins binds to methylated CpG 
islands and mediates transcriptional repression of affected genes. The MBD family of proteins 
consists of five members: MeCP2, MBD1, MBD2, MBD3 and MBD4 (Berger and Bird, 2005). 
All MBD proteins contain a similar methyl binding domain (MBD) of about 75 amino-acid 
residues (Fig 3). Sequence alignment of MBD proteins reveals several highly conserved residues 
on the interface between MBD and methylated DNA which are responsible for recognition of the 
methyl-CpG steps. Among these, MeCP2 is capable of binding to a single, symmetrically 
methylated CpG dinucleotide and binds to chromosomes at sites known to contain methylated 
DNA. MBD1 is a transcriptional regulator characterized by two or three CXXC domains that 
bind methylated CpG islands of the tumor suppressor genes and suppress transcription (Patra et 
al., 2001). MBD2 has been reported to have DNA demethylase activity along with repressor 
function (Bhattacharya et al., 1999). MBD4 is a repair enzyme of the DNA-glycosylase family 
and MBD3 apparently lacks specific methylated DNA-binding capability although it has a high 
degree of sequence similarity with MBD2. The finding that the hyper-methylation of promoters 
is associated with silencing of several genes in human prostate cancer is noted in the literature 
but the study of the respective enzymes and their relative levels, and repressor proteins is 
lacking.  
MBD1-Methyl Binding Domain protein 1: 
MBD1 is the biggest MBD family member and is known to act as a transcriptional 
repressor both in vivo and in vitro (Fig 3).Depending on the splicing isoform, it can connect 
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methylated as well as unmethylated DNA. Like the other family members, MBD1 associates 
with chromatin modifiers such as the Suv39h1–HP1 complex to enhance DNA methylation-
mediated transcriptional repression (Zhang et al. 1999). The functional value of MBD1 was 
demonstrated in human HeLa cells, where MBD1 was shown to combine with the H3K9 
methyltransferase SETDB1. During S phase the MBD1–SETDB1 complex is recruited to 
chromatin by the chromatin assembly factor CAF1 to establish new H3K9 methyl marks. An 
MBD1 mouse knockout has been obtained, but no severe developmental defects were found. 
MBD1-null mice had a normal morphology and appeared healthy, although they carried a 
number of minor neural defects like reduced hippocampal neurogenesis and had problems with 
spatial learning. Another interesting feature of this knockout was reduced genomic stability and 
an increase in expression of the intracisternal-a particle retrotransposon (Fujita et al., 2000).  
 
MBD2- Methyl Binding Domain protein 2: 
The second member of the MBD family, MBD2, is a 44-kDa protein which shares 
widespread sequence homology with MBD3. MBD2 is able to bind methylated CpGs in vitro 
and in vivo and confer DNA methylation mediated transcriptional silencing through its 
repression domain (Fig 3).The suppression established by MBD2 is responsive to HDAC 
inhibitors, in line with its association with HDAC1 and HDAC2 in the Mi-2/NuRD chromatin 
remodeling complex (Zhang et al. 1999). MBD2-null mice developed usually and remained 
viable and fertile, although MBD2-null mothers fail to nurture their pups properly. The 
association between the loss of MBD2 and the observed maternal behavior is unclear. MBD2, 
however, does play a role in helper T-cell differentiation. Normally, the induction of IL-4 during 
differentiation requires the GATA3 activator, yet, in MBD2-null mice GATA-3 is no longer 
needed for IL-4 induction and as a result IL-4 is ectopically expressed in undifferentiated helper 
T cells. 
 
MBD3- Methyl Binding Domain protein 3:  
MBD3 has extensive sequence similarity to MBD2 (Hendrich and Bird., 1998). It is 
expressed as several splice variants, some of which disrupt the MBD. MBD3 mRNA is 
expressed in the adult brain. In the brain, MBD3 expression can be detected in high levels in 
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neuroepithelial cells whereas MBD2 is barely detected (Jung et al., 2002). The protein has been 
identified as a component of the Mi-2/NuRD transcriptional co-repressor complex that includes 
Mi-2 ATPase, HDAC, and other proteins (Fig 3).Yet in vitro, mammalian MBD3 has little if any 
methyl-CpG-binding activity, likely because of amino acid substitutions within the MBD. MBD3 
can be transiently induced by kindling or transient ischemia in rodent hippocampus, suggesting 
that these proteins may be involved in alteration of gene expression upon lesions (Francis et al, 
2002). Therefore, the case for the Xenopus orthologue of MBD3 which contains a MBD with 
methyl-CpG-binding activity it is unlikely that mammalian MBD3 plays a role in methylation 
dependent transcription repression (Fraga et al., 2003). MBD3 is a necessary component for 
NuRD complex and involved in multiple gene regulatory pathways for embryogenesis. 
 
MBD4- Methyl Binding Domain protein 4:  
MBD4 includes a MBD similar to that of MeCP2, while the COOH-terminal domain is 
homologous to bacterial DNA repair enzymes. Although MBD4 is capable of binding to methyl-
CpG sites, it has a high affinity for 5mCpG-TpG mismatched sites, and the DNA repair domain 
provides DNA N-glycosylase activity at G-T mismatches (Fig 3).So MBD4 is ideally suited to 
function in the repair of point mutations that result from spontaneous deamination of 5-
methylcytosine to thymine (Hendrich et al., 1999). In addition, MBD4 (also known as MED1) 
binds to the MLH1 DNA mismatch repair protein in vivo. Expression of a MBD4 mutant missing 
the MBD induces microsatellite instability in cell lines; implicate MBD4 in this form of DNA 
repair as well (Bellacosa et al., 1999). Yet, in an in vitro assay, nuclear extracts containing 
MBD4 make mismatch repair independently of target CpG methylation status. 
 
MECP2- Methyl CpG binding protein 2:   
Methyl CpG binding protein 2 is a gene that provides instructions for making its protein 
product, MECP2, also referred to as MeCP2 (Amir et al., 1999). MECP2 appears to be necessary 
for the normal function of nerve cells. The protein seems to be mainly important for mature 
nerve cells, where it is there in high levels. The MeCP2 protein is likely to be occupied in turning 
off (repressing or silencing) of several other genes. This prevents the genes from production 
proteins when they are not needed. Within the brain, the MeCP2 protein is essential for the 
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function of nerve cells (neurons) and is present in high levels in mature neurons (Fig 3). This 
protein likely act a role in maintaining connections (synapses) between neurons, where cell-to-
cell contact occurs. Many of the genes that are known to be regulated by the MeCP2 protein play 
a role in normal brain function, mostly the maintenance of synapses (Amir et al., 1999). 
 
 
 
Only the general structure of the protein is shown—some have alternative isoforms. N-termini are on the 
left, C-termini are on the right. Abbreviations: MBD, methyl-binding domain; TRD, transcription 
repression domain; GR, alternating glycine and arginine repeats. 
(Adapted from Sansom et al, Nature Clinical Practice Oncology, 2007) 
 
MBD Proteins and Gene Silencing Mechanism: 
The MBD sequence motif was defined by molecular analysis of prototype of MBD 
protein and MeCP2 (Nan et al., 1993). This MBD sequence motif was found to be both 
necessary and sufficient to be direct specific interaction with methyl-CpG-containing DNA 
fragments. It consists of around 70 amino acids and represents the sole sequence feature found in 
common all of the MBD family members. The single exclusion to this rule is case of the MBD2 
Figure 3: Schematic structure of the major MBD family members. 
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and MBD3 which are nearly identical in amino acid sequences, and have common gene 
structures and are believed to have arisen from an ancient duplication in all the evolution of the 
vertebrate lineage. MeCP2 protein binds methylated CpG sites at gene promoters and promotes 
gene silencing by associating with Sin3A and Histone Deacetylases to form co-repressor 
complexes and through its interaction with CREB selectively regulates active BDNF gene 
transcription (Akbarian & Huang, 2009).  
 
 
 
 
MBD protein mediated gene silencing involves interaction of MBD proteins with different partners such 
as Histone Deacetylase (HDAC), Histone methyltransferases and chromatin remodelling complexes  
to form heterochromatin and prevent transcriptional activation of genes. 
(Adapted from Kubota et al., The Mechanisms of DNA Replication, 2013) 
 
Figure 4: MBD Proteins Mediated Gene Silencing and Transcriptional inactivation. 
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Action of MBD proteins in promoting cancer via gene silencing: 
It has recently been recognized that cancer is a manifestation of both abnormal genetic 
and epigenetic events (Jones, 2003). Deregulated epigenetic controls, which typically are 
represented by abnormal DNA methylation patterns such as global hypomethylation and region 
specific hypermethylation, are a trademark of most cancers. Aberrant hypermethylation of 
promoter CpG islands and the resulting transcriptional silencing is nowadays a widely accepted 
mechanism of inactivation of tumor suppressor genes in cancer that actively contributes to 
tumorigenesis. Treatment of cancer cells with the demethylating agent 5-aza-2′-deoxycytidine 
results in passive loss of CpG island methylation, MBD release, and gene re-expression, 
strengthening the notion that association of MBDs with methylated promoters is methylation-
dependent (Fig 5). The existence of these profiles provides a powerful set of markers for 
outlining the disruption of critical pathways in tumorigenesis and for deriving sensitive 
molecular detection strategies for virtually every human tumor type (Wade, 2001). 
The systematic study of DNA methylation patterns in human cancer cell lines has shown 
that these are appropriate models for this type of study as they show methylation patterns that 
resemble their corresponding tumor types. The selectivity of MBDs for methylated DNA and 
their transcriptional repression properties suggest that they could exert their function in 
methylated promoters (Fig 5).The occurrence of MBD proteins in the methylated promoter of a 
gene in cancer was first shown in 2000, when Magdinier and Wolffe (Magdinier and Wolffe, 
2001) recognized MBD2 in the methylated promoter of p16INK4a in colon cancer cells. Human 
MBD genes are considered as housekeeping genes because they are widely expressed in somatic 
tissues. Given the epigenetic function of MBD proteins in regulating gene expression, MBDs 
may be concerned in cancer development by affecting the expression of cancer related genes. In 
fact, there is increasing evidence that aberrant expression of MBD proteins is associated with 
human cancers (Patra et al., 2003). The MBD2 gene is mapped to the conserved region within 
human chromosome 18q21. A recent finding also suggests that MBD2 has potential DNA 
demethylase activity (Bhattacharya et al., 1999), implying that it might reconcile gene activation 
in addition to transcriptional suppression. However, two subsequent studies could not 
demonstrate any demethylase activity of MBD2, and this inconsistency in the functions of 
MBD2 remains to be resolved. So many studies in human cancer research have demonstrated 
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that the MBD2 protein plays a role in tumorigenesis. Moreover, a significant reduction in MBD2 
mRNA expression was found in human colorectal and gastric cancerous tissues (Kanai et al., 
1999) and peripheral blood lymphocytes in bladder cancer patients, implying a protecting role 
for MBD2 in tumorigenesis. MBD2 protein expression and its demethylase activity were 
detected in normal human prostate tissue but not in cancerous tissue (Patra et al., 2002). These 
differences between types of cancers in the abundance of MBD2 levels may reflect different 
roles for MBD2 either in transcriptional repression or in the demethylation process. 
 
 
 
 
MeCP2, MBD2 and MBD3 interact with HDACs to bring about transcriptional repression whereas 
MBD1 binds with DNMT1 and acts to silence the hypermethylated promoter regions. MBD4 participates 
in DNA repair where it removes thymines (yellow dots) formed by oxidative deamination of methyl    
cytosines.  MBD bind to the various hypermethylated promoters and are implicated in different MBD 
proteins thus form an important component of the epigenetic regulatory systems. 
 
 
Figure 5: A simplified diagram depicting the modes of action of the different MBD proteins. 
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OBJECTIVES OF THE PROJECT 
 
1. Study of the gene expression status of the different MBD proteins - MeCP2, MBD1, 
MBD2, MBD3 and MBD4 in MDA-MB-231 breast cancer cell line. 
 
2. Study of the effect of various epigenetic modulators such as Trichostatin A (TSA), 
and Sulforaphane (SFN) on the expression of the different MBD genes after 24 
hours treatment at the transcriptome level. 
 
3. Comparative analysis of the effect of the various epigenetic modulators on the 
different MBD proteins and on the survival of MDA-MB-231 breast cancer cells. 
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MATERIALS AND METHODS 
 
1. In vitro cell culture: 
MDA-MB-231 human mammary tumor cells were cultured and maintained in DMEM 
(Dulbecco’s Modified Eagle’s Medium) supplemented with 10% (v/v) FBS (Fetal Bovine 
Serum) and 100 IU/mL Penicillin & 0.1 mg/mL streptomycin in a humified atmosphere of 5% 
CO2 at 37 °C. 
 
2. Drug treatment with AZA and SAM: 
The cells (3 × 10
5
/well) were grown in 6-well plates (40–50% confluent) and then treated with 
TSA (10,20,25,50,75,100,200,250,500 nM) and SFN (5,7,10,15,20,25,50,75,100 μM) mixed in 
DMEM supplemented with 5% FBS to determine the optimum doses for the drugs. Cells were 
then incubated at 37º C in complete growth medium for 24 and 48 hrs. Control cells were treated 
identically, except that no drugs were added to the cell medium.  
 
3. Cell Viability Analysis by colometric MTT Assay: 
Cell viability analysis and cytotoxicity studies were performed using the MTT assay based on the 
observation that the mitochondria in living cells can catalyze MTT molecules to a 
colorimetrically detectable dye. The drug-treated cells were washed in PBS, trypsinized and then 
seeded in 96-well plate at 105 cells/well (200 μl).100 μl of MTT solution (0.8 mg/ml) was then 
added to each well and the cells were incubated at  37º C for 4 hrs. Thereafter, DMSO was added 
to all wells and mixed thoroughly to dissolve the dark blue precipitate and incubated for 15 mins 
at room temperature. The absorbance of samples was determined at a wavelength of 590 nm. The 
extent of cytotoxicity was defined as the relative reduction of the optical density (OD), which 
correlated to the amount of viable cells in relation to cell control (100%). The cell viability was 
plotted in a graph and the IC50 was calculated accordingly to decide the optimum dosage of the 
drugs for further studies. 
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4. Flow Cytometry Analysis of the effects of epigenetic drugs on cell cycle (FACS): 
Flow cytometry analysis of PI stained nuclei was done to assess the effects of epigenetic drugs 
TSA and SFN on the cell cycle distribution. TSA (100 and 250 nM) and SFN (10 and 20 μM) 
treated cells were incubated in DMEM with 5% FBS for 24 and 48 hrs. The cells were then 
trypsinized, collected by centrifugation, washed twice with PBS and then fixed in 90% ice-cold 
methanol. After incubation at -20℃ for 1 hr, cells were centrifuged and resuspended in PBS 
followed by treatment with RNaseA (500 U/ml) to digest the residual RNAs and stained with 
propidium iodide (50 ng/ml). Samples were incubated for 30 min at room temperature and cell 
cycle analysis was performed with a Becton–Dickinson fluorescence-activated cell sorter 
(FACS). 
 
5. Chromatin condensation analysis after 24 hours drug treatment by Hoechst staining: 
After treatment with drugs, the cells were stained with Hoechst 33342 stain (1 μg/ml) and 
incubated for 10 min at 37ºC and images were taken under UV filter using Epi-fluorescene 
Microscope at 400 X magnification with an excitation wavelength of 355-366 nm and an 
emission wavelength of 465-480 nm. 
 
6. Extraction of Total RNA: 
Total RNA was extracted from MDA-MB 231 cells by using the Trizol reagent. The drug treated 
cells (5-10 X 10
6
 cells) were washed with 1 ml ice cold PBS, then trypsinized and then treated 
with 1 ml Trizol. 0.2 ml of chloroform (0.2 ml per 1 ml of TRI Reagent) was added to the tubes, 
shaken vigorously for 30 seconds by hand/vortex mixer and incubated at RT for 10 mins. The 
samples were centrifuged at 12,000 X g for 15 mins at 4 ° C. Following centrifugation, the 
mixture separates into lower red, phenol-chloroform phase, an interphase, and a colorless upper 
aqueous phase containing the RNA.  The upper aqueous phase was removed without disturbing 
the interphase and collected in a fresh tube.  0.5 ml isopropyl alcohol per 1 ml of TRI Reagent 
was added to the tubes. The tubes were then incubated at RT for 10 minutes and then centrifuged 
at not more than 12,000 x g for 10 minutes at 4 ° C. The supernatant was removed completely. 
The RNA precipitate, often invisible before centrifugation, forms a gel-like pellet on the side and 
bottom of the tube. The pellet was washed with 1ml of 75% ethanol per 1 ml of TRI Reagent. 
The samples were mixed by vortexing and centrifuged at no more than 7,500 x g for 5 minutes at 
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4 ° C.  The pellet was air-dried by keeping the RNA pellet containing tube opened in working 
bench for 15 mins. The RNA was dissolved in50 μl EPC-treated water by passing solution a few 
times through a pipette tip. The RNA was stored at - 20° C for further use or immediately 
processed for cDNA synthesis. 
 
7. Quantitative Estimation of RNA Concentration by Spectrophotometric Analysis: 
The concentration of the extracted total RNA was quantified by measuring the absorbance at 260 
nm in a spectrophotometer (ELICO, BL 200 Bio Spectrophotometer, double beam) and 
calculated by using the formula as given below: 
Total RNA (μg /ml) = OD260 × 40 × Dilution factor. 
 
8. Quantitative Estimation of RNA Concentration by Denaturing Gel   Electrophoresis: 
The extracted RNA was run on a denaturing agarose gel and the quantity of RNA estimated from 
the band intensity. For denaturation gel (40 ml), 0.6 g agarose (Sigma), 28.8 ml dH2O (Sigma), 
7.2 ml formaldehyde (Sigma), 4 ml 10X MOPS buffer were mixed properly. About 2 μl (2μg) of 
the total RNA was mixed with 18 μl 1X Reaction Buffer (2μl of 10X MOPS Buffer, 4 μl 
formaldehyde, 10 μl formamide (Sigma) ,2 μl 0.2 mg/ml Etbr (Sigma)) and incubated at 55 °C 
for 1 hr. It was then cooled on ice and loaded in the wells of the denaturing gel. 
 
9. First strand cDNA synthesis: 
Total RNA (4 g) was used for first strand cDNA synthesis by reverse transcription using 
RevertAid
TM 
First Strand cDNA Synthesis Kit (Fermentas) in a thermocycler (Biorad). The RNA 
was incubated with 1 l of oligo (dT)18  primers (100 μM, 0.2 μg/μl) and 12 μl of nuclease-free 
water at 65 C for 5 min. The reaction was cooled on ice to allow the primers to anneal to the 
RNA, then spin down and placed on ice again after which the following components were added 
to the reaction in order; 4 l of 5X Reaction Buffer, 1 l of RibolockTM RNase inhibitor (20 
U/l), 2 l of 10 mM dNTPs and 1.0 L of RevertAidTM M-MuLV-Reverse Transcriptase (200 
U/l). The reagents were gently mixed and incubated for 1 hr at 42C. Heating at 70C for 5 min 
terminated the reaction and the synthesized cDNA was stored at –20 0 C for further use. 
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10. Gene-specific semi-quantitative PCR for amplification of the desired genes: 
 
The PCR reaction mixtures, in a 25 μl volume, contained 17 μl of dH2O (Sigma), 2.5 μl of 1X 
PCR buffer (Sigma), 0.5 μl of dNTP (0.2 mM, Sigma), 1.5 μl of MgCl2 (1.5 mM, Sigma), 0.5 μl 
each of the forward and reverse primers (0.2 μM, Sigma) of MBD1, MBD2, MBD3, MBD4, 
MeCP2 and 0.5 μl Taq DNA-polymerase (1U/μl, Himedia). 2 μl of each cDNA sample was 
added. PCR amplifications of MBD1, MBD2, MBD3 and MBD4 were performed in a thermal 
cycler (Biorad) by initial denaturation at 94° C for 1 min, followed by 30 cycles of denaturation 
at 94° C for 20 secs, annealing at 57 ° C for 20 secs, and extension at 72° C for 30 secs, followed 
by an final extension step at 72° C for 5 mins. The constitutively expressed housekeeping gene, 
β-actin was used as a positive control to ensure high quality. RT-PCR products were then 
analyzed by 1% agarose gel electrophoresis containing ethidium bromide (0.05%). The primer 
sequences used for the PCR reaction are shown in Table 1.  
Table 1.Table showing the forward and backward primers and their amplicon sizes. 
 
 
 
 
 
PRIMER 
 
 
 
 
TYPE 
 
 
 
 
SEQUENCE 
   Table 1.Table showing t he sequence of the forward and bac kward primers.  
 
 
 
 
AMPLICON (bp) 
 
 
 
MBD1 
 
 
Forward 
 
 
 
5’  CCTGGGTGCTGTGAGAACTGT   3’ 
107  
           
 
 
 
 
 
 
 
 
 
                                                                                                             107   
Reverse 
 
 
 
5’  TTGAAGGCAATTCTCTGTGCTC   3’ 
 
 
 
MBD2 
 
 
 
Forward 
 
 
 
 
5’ AGGTAGCAATGATGAGACCCTTTTA   3’ 
                   
 
 
 
 
 
    
 
 
 
 
 
 
 
             116  
 
Reverse 
 
 
 
5’  TAAGCCAAACAGCAGGGTTCTT   3’ 
 
MBD3 
 
 
 
Forward 
 
 
 
 
5’  CCGCTCTCCTTCAGTAAATGTAAC  3’ 
          
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                             101  
 
Reverse 
 
 
 
 
5’  GGCTGGAGTTTGGTTTTCAGAA   3’ 
 
MBD4 
 
 
 
Forward 
 
 
 
 
5’  AGACCCGCCGAATGACCT   3’ 
           
 
 
 
 
 
 
 
 
 
 
 
 
 
                               144  
 
 
Reverse 
 
 
5’  GCACCAAACTGAGCAGAAGCG   3’ 
 
MeCP2 
 
 
 
Forward 
 
 
 
 
5’  TGACCGGGGACCCATGTAT   3’ 
          
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                        145  
 
Reverse 
 
 
 
 
5’  CTCCACTTTAGAGCGAAAGGC   3’ 
 
β-ACTIN 
 
 
 
Forward 
 
 
 
 
5’   CTGGAACGGTGAAGGTGACA  3’ 
          
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                           140   
Reverse 
 
 
 
5’   AAGGGACTTCCTGTAACAACGCA   3’ 
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11.  Relative Gene Expression Analysis after drug treatment by Real-Time PCR: 
Quantitative estimation of the expression of the MBD genes after drug treatment was done via real-time 
PCR analysis. cDNA was used to analyze the expression of MBD genes along with β-Actin as a house 
keeping gene.  
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RESULTS AND DISCUSSION 
 
1. Cell Viability Analysis by colometric MTT Assay: 
Cytotoxicity studies were performed to determine the effect of epigenetic drugs such as TSA and 
SFN (inhibitors of Histone Deacetylases (HDACs)) on the expression of MBD genes. In order to 
determine the optimum dosage, different concentrations of the drugs were considered and the 
treatment was done for different time intervals. The results obtained from the MTT assays are 
given below: 
 
(A) 
 
(B) 
Figure 6: The effect of different concentrations of drug TSA (10,20,25,50,75,100,200,250,500 
nM) at different time intervals of 24 hrs (A) and 48 hrs (B) on the survival of MDA-MB-231 
breast cancer cells.  
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(A) 
 
(B) 
 
Figure 7: The effect of different concentrations of drug SFN (5, 7,10,15,20,25,50,75,100 μM) at 
different time intervals of 24 hrs (A) and 48 hrs (B) on the survival of MDA-MB-231 breast 
cancer cells.  
In general, cell survival levels declined progressively with an increased dose of both the 
epigenetic drugs (Fig 6 & 7). Treatment with increasing doses of both TSA and SFN showed a 
drastic decline in cell survival. From this assay, 250 nM of TSA and 10 μM of SFN were chosen 
as the optimum doses for further MBD expression studies. 
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2. Flow Cytometry Analysis of the effects of epigenetic drugs on cell cycle (FACS): 
Flow Cytometric analysis was done to assess the effect of the epigenetic drugs on the cell cycle 
and consequently co-relate these effects to cancer progression. HDAC inhibitors TSA and SFN 
are known to effectively inhibit the action of HDACs and result in transcriptional activation. The 
results of the FACS study are represented below (Fig 8 & 9). As shown below, breast cancer 
cells were arrested in different phases in a dose and time dependent manner. In comparison to 
control, cells treated with TSA and SFN, exhibited reduction in G1-phase cells, decreased 
percentage of G2 population and drastic increase in apoptotic cells.  Thus, the HDAC inhibitors 
TSA and SFN induce differentiation, growth arrest and apoptosis in MDA-MB-231 cells.  
  
(A)                                                                           (B) 
Figure 8: Cell cycle distribution of MDA-MB-231 cells after treatment by two different doses of 
TSA (100 and 250 nM) for different time intervals of 24 hrs (A) and 48 hrs (B).  
The alterations in the cell cycle distributions were distinct at different time intervals (24 & 48 
hrs) as well as at low versus high doses. At a low dose of TSA (100 nM), there is a decrease in 
G1 phase cells, S and G2 populations but increase in apoptotic cell percentage. At higher dosage 
(250 nM), there is a drastic decrease in G1, S, G2 populations while apoptosis is greatly elevated. 
Thus TSA affects all the stages of cell cycle, arresting cell progression in each successive stage 
and ultimately increasing the rate of apoptosis of the cell population.  
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(A)                                                                           (B) 
Figure 9: Cell cycle distribution of MDA-MB-231 cells after treatment by two different doses of 
SFN (5 and 10 μM) for different time intervals of 24 hrs (A) and 48 hrs (B). 
The alterations in the cell cycle distributions were distinct at different time intervals (24 & 48 
hrs) as well as at low versus high doses. At a low dose of SFN (5 μM), there is a decrease in G1 
phase cells, S and G2 populations but increase in apoptotic cell percentage. At higher dosage 
(250 nM), there is a drastic decrease in G1, S, G2 populations while apoptosis is greatly elevated. 
However, the effect of these drugs increases with time interval, the decrease in G1 phase cells is 
more after 48 hrs treatment; however, there was little effect on the other cell populations with 
increased time. Thus SFN is found to be a potent inhibitor of cell cycle progression, greatly 
increasing apoptosis. MBD proteins are known to interact with HDACs to repress transcriptional 
activity via heterochromatin formation. As the HDAC inhibitors effectively trap HDAC and 
prevent them to associate with MBD proteins, there is a possibility that the action of MBD 
proteins can be disrupted. Hence, treatment with HDACi affects the activity of MBD proteins. 
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3. Chromatin condensation analysis after drug treatment by Hoechst staining: 
Nuclear chromatin condensation in drug treated MDA-MB-231 cell by Hoechst staining is a 
visually detectable assay to quantify the amount of apoptotic cells after drug treatment. The blue-
fluorescent Hoechst 33342 brightly stains the condensed chromatin of apoptotic cells and less 
brightly stains the normal chromatin of live cells (Fig 10 & 11). After FACS analysis, the drug 
treated cells were stained with Hoechst dye to estimate the effectiveness of each drug and the 
rate of apoptosis inflicted by each drug. The results of the Hoechst staining assay are given 
below: 
 
(A)                                               (B)                                          (C) 
Fig 10: Nuclear chromatin condensation in TSA treated MDA-MB-231 cell after 24 & 48 hrs. 
 
                    (A)                                              (B)                                              (C) 
 
Fig 11: Nuclear chromatin condensation in SFN treated MDA-MB-231 cell after 24 & 48 hrs. 
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4. Relative Gene Expression Analysis after drug treatment by RT-PCR: 
In general, there is over-expression of all the MBD genes in cancer. It is well documented that 
MeCP2, MBD2 and MBD3 interacts with HDACs in gene silencing, hence they showed 
decreased expression in relation to normal expression of MBD1 and MBD4 after treatment with 
HDAC inhibitor TSA and SFN. MBD2 is mainly involved in DNA repair; hence its expression 
is mostly uniform upon treatment with various epigenetic drugs.  
 
Figure 12: Relative expression of the different MBD genes with respect to β-actin (a house 
keeping gene) in TSA treated MDA-MB 231 cells. 
 
 
Figure 13: Relative expression of the different MBD genes with respect to β-actin (a house 
keeping gene) in SFN treated MDA-MB 231 cells. 
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CONCLUSION 
 
In this study, we have shown the effect of different epigenetic modulators such as TSA and SFN 
on the expression of different members of the MBD group of proteins. MBD proteins interact 
with HDAC to bind to the methylated cytosine bases in CpG islands of the hypermethylated 
promoter regions and inhibit transcriptional activity. Hence it can be safely assumed that 
inhibiting MBDs can provide a means of negating its effect on transcriptional activity. Hence, 
inhibiting the HDACs by HDAC inhibitors such as TSA and SFN will serve as a means to 
restrict MBD proteins and help in transcriptional reactivation of silenced genes such as tumor 
suppressors, cell cycle regulatory and apoptosis inducing genes. The turning on of crucial tumor 
suppressor genes may be an efficient means to counteract malignant transformation; hence MBD 
proteins can be regarded as novel prognostic targets for cancer therapy. 
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